ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells

B-cell precursor-acute lymphoblastic leukemia modulates the bone marrow (BM) niche to become leukemia-supporting and chemo-protective by reprogramming the stromal microenvironment. New therapies targeting the interplay between leukemia and stroma can help improve disease outcome. We identified ActivinA, a TGF-β family member with a well-described role in promoting several solid malignancies, as a factor favoring leukemia that could represent a new potential target for therapy. ActivinA resulted over-expressed in the leukemic BM and its production was strongly induced in mesenchymal stromal cells after culture with leukemic cells. Moreover, MSCs isolated from BM of leukemic patients showed an intrinsic ability to secrete higher amounts of ActivinA compared to their normal counterparts. The pro-inflammatory leukemic BM microenvironment synergized with leukemic cells to induce stromal-derived ActivinA. Gene expression analysis of ActivinA-treated leukemic cells showed that this protein was able to significantly influence motility-associated pathways. Interestingly, ActivinA promoted random motility and CXCL12-driven migration of leukemic cells, even at suboptimal chemokine concentrations, characterizing the leukemic niche. Conversely, ActivinA severely impaired CXCL12-induced migration of healthy CD34+ cells. This opposite effect can be explained by the ability of ActivinA to increase intracellular calcium only in leukemic cells, boosting cytoskeleton dynamics through a higher rate of actin polymerization. Moreover, by stimulating the invasiveness of the leukemic cells, ActivinA was found to be a leukemia-promoting factor. Importantly, the ability of ActivinA to enhance BM engraftment and the metastatic potential of leukemic cells was confirmed in a xenograft mouse model of the disease. Overall, ActivinA was seen to be a key factor in conferring a migratory advantage to leukemic cells over healthy hematopoiesis within the leukemic niche.

[1]  B. Walzog,et al.  Coronin 1A, a novel player in integrin biology, controls neutrophil trafficking in innate immunity. , 2017, Blood.

[2]  David M. Reif,et al.  An Introduction to Terminology and Methodology of Chemical Synergy—Perspectives from Across Disciplines , 2017, Front. Pharmacol..

[3]  D. Davis,et al.  Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling. , 2017, Cancer letters.

[4]  Jennifer Enciso,et al.  Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis , 2017, Front. Immunol..

[5]  M. Hsiao,et al.  Dysregulation of RUNX2/Activin-A Axis upon miR-376c Downregulation Promotes Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. , 2016, Cancer research.

[6]  M. Sperandio,et al.  Rac GTPase Activating Protein ARHGAP25 Regulates Leukocyte Transendothelial Migration in Mice , 2016, The Journal of Immunology.

[7]  Liang Wu,et al.  Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3 , 2016, Scientific Reports.

[8]  J. McCubrey,et al.  Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. , 2016, Biochimica et biophysica acta.

[9]  C. Mullighan,et al.  Acute Lymphoblastic Leukemia in Children. , 2015, The New England journal of medicine.

[10]  W. El-Rifai,et al.  Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinoma , 2015, Oncotarget.

[11]  T. Salo,et al.  Low miR-143/miR-145 Cluster Levels Induce Activin A Overexpression in Oral Squamous Cell Carcinomas, Which Contributes to Poor Prognosis , 2015, PloS one.

[12]  Mohsin Bashir,et al.  Activin-A signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancer , 2015, npj Breast Cancer.

[13]  Xiancheng Liu,et al.  Activin A regulates proliferation, invasion and migration in osteosarcoma cells. , 2015, Molecular medicine reports.

[14]  H. Mayani,et al.  Bone Marrow Cells in Acute Lymphoblastic Leukemia Create a Proinflammatory Microenvironment Influencing Normal Hematopoietic Differentiation Fates , 2015, BioMed research international.

[15]  Y. Hseu,et al.  VAV3 Oncogene Expression in Colorectal Cancer: Clinical Aspects and Functional Characterization , 2015, Scientific Reports.

[16]  Yan Cao,et al.  Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia , 2015, Haematologica.

[17]  M. Rönty,et al.  Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth. , 2015, Experimental cell research.

[18]  C. Andl,et al.  Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion , 2014, Cancers.

[19]  R. Pieters,et al.  Disturbed CXCR4/CXCL12 axis in paediatric precursor B‐cell acute lymphoblastic leukaemia , 2014, British journal of haematology.

[20]  H. Katoh,et al.  Dock4 forms a complex with SH3YL1 and regulates cancer cell migration. , 2014, Cellular signalling.

[21]  S. Srinivasan,et al.  Sotatercept in patients with osteolytic lesions of multiple myeloma , 2014, British journal of haematology.

[22]  R. Pieters,et al.  Disturbed CXCR4/CXCL12 Axis In Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia , 2013 .

[23]  S. Rutella,et al.  How I treat relapsed childhood acute lymphoblastic leukemia. , 2012, Blood.

[24]  Chien-Feng Li,et al.  Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence. , 2012, Cancer research.

[25]  Gábor Sirokmány,et al.  ARHGAP25, a novel Rac GTPase-activating protein, regulates phagocytosis in human neutrophilic granulocytes. , 2012, Blood.

[26]  D. Teachey,et al.  Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. , 2011, Blood.

[27]  P. Lipp,et al.  Protein kinase C: the "masters" of calcium and lipid. , 2011, Cold Spring Harbor perspectives in biology.

[28]  E. Sison,et al.  The bone marrow microenvironment and leukemia: biology and therapeutic targeting , 2011, Expert review of hematology.

[29]  S. Sozzani,et al.  The yin and yang of Activin A. , 2011, Blood.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  D. Campana,et al.  Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. , 2011, Blood.

[32]  Martin A. Schwartz,et al.  Cell adhesion: integrating cytoskeletal dynamics and cellular tension , 2010, Nature Reviews Molecular Cell Biology.

[33]  J. V. van Dongen,et al.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. , 2010, Blood.

[34]  Charles P. Lin,et al.  Bone progenitor dysfunction induces myelodysplasia and secondary leukemia , 2010, Nature.

[35]  R. Weissleder,et al.  Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease , 2010, Proceedings of the National Academy of Sciences.

[36]  Chang-Yi Hsieh,et al.  Activin A Enhances Prostate Cancer Cell Migration Through Activation of Androgen Receptor and Is Overexpressed in Metastatic Prostate Cancer , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  V. Jala,et al.  Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. , 2009, Blood.

[38]  Angela C. Colmone,et al.  Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells , 2008, Science.

[39]  Amanda Y. Chan,et al.  Tumorigenesis and Neoplastic Progression The Guanine Nucleotide Exchange Factors Trio , Ect 2 , and Vav 3 Mediate the Invasive Behavior of Glioblastoma , 2010 .

[40]  M. Waxham,et al.  Ca2+/Calmodulin-dependent Protein Kinases , 2008, Cellular and Molecular Life Sciences.

[41]  T. Nagasawa,et al.  Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. , 2006, Immunity.

[42]  B. Vanderhyden,et al.  Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. , 2005, Molecular cancer research : MCR.

[43]  S. Nishikawa,et al.  TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell–derived endothelial cells , 2003, The Journal of cell biology.

[44]  G Mann,et al.  High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia , 2001, British journal of haematology.

[45]  S. Pangas,et al.  Activin Signal Transduction Pathways , 2000, Trends in Endocrinology & Metabolism.

[46]  M. Ogimoto,et al.  Negative regulation of apoptotic death in immature B cells by CD45. , 1994, International immunology.

[47]  A. Edelman,et al.  Ca(2+)-calmodulin-dependent protein kinases Ia and Ib from rat brain I. Identification, purification, and structural comparisons. , 1992, The Journal of biological chemistry.

[48]  Qing Lu,et al.  Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling , 2017, International immunopharmacology.

[49]  Claire Schwab,et al.  Acute lymphoblastic leukaemia. , 2011, Methods in molecular biology.

[50]  R. Kalluri,et al.  Contribution of bone microenvironment to leukemogenesis and leukemia progression , 2009, Leukemia.

[51]  K. Mimori,et al.  Activin A Causes Cancer Cell Aggressiveness in Esophageal Squamous Cell Carcinoma Cells , 2008, Annals of surgical oncology.

[52]  杉山 立樹.  Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches , 2007 .

[53]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.